Kidney transplantation is the treatment of choice for end-stage renal disease; however, long-term graft survival continues to be jeopardized by rejection, chronic allograft injury, and infection. Histopathological assessment of renal allograft biopsies remains the diagnostic gold standard, yet interpretation variability has historically hindered consistency across institutions and clinical trials. To address this, international consensus efforts established the Banff Classification, with biennial updates refining and expanding its scope. This review outlines the evolution of renal allograft pathology classification systems, emphasizing key Banff revisions that introduced diagnostic criteria for T cell-mediated and antibody-mediated rejection (ABMR), borderline changes, chronic active rejection, and polyomavirus nephropathy. Modern frameworks increasingly incorporate morphology, immunohistochemistry, and emerging molecular diagnostics to improve accuracy and reproducibility. In clinical practice, the Banff system informs immunosuppressive strategies, guides treatment response monitoring, supports prognostication, and standardizes endpoints in clinical trials. Ongoing challenges include interobserver variability, sampling limitations, and restricted access to advanced molecular and digital technologies in resource-limited settings. Future directions point toward integrating multi-omics, digital pathology, and artificial intelligence to create a unified, patient-centered diagnostic platform that extends Banff's legacy of consensus and adaptability.
Qasim et al. (2025) studied this question.